Antibodies | Seroprevalence of Measles, Mumps, Rubella, and Varicella IgG Antibodies in Adolescents Following MMR Vaccination

This study reveals that the seroprotection rates against measles and mumps in fully vaccinated adolescents are significantly lower than expected, suggesting a need to re-evaluate serological testing criteria and booster timing in vaccine immunization strategies and disease surveillance.

 

Literature Overview

The article titled "Seroprevalence of IgG Antibodies to Measles, Mumps, Rubella and Varicella in Adolescents with Documented Two-Dose MMR Vaccination: Cross-Sectional Study," published in the journal Antibodies, systematically explores the serological protection levels in Russian adolescents aged 13–15 years who have completed two doses of the MMR vaccine and experienced natural varicella infection. The study aims to identify immunity gaps and guide booster immunization strategies.

Background Knowledge

Although measles, rubella, mumps, and varicella are vaccine-preventable diseases, breakthrough infections and outbreaks still occur despite high vaccination coverage, raising concerns about the durability of vaccine-induced immunity. Currently, the waning of antibody titers for measles and mumps over time is a major challenge, and there is a lack of unified standards for protective thresholds. Particularly in adolescents, inadequate primary immune responses or secondary vaccine failures may weaken herd immunity barriers. This study addresses this by conducting a large-scale serological survey to quantify the concentration distribution of pathogen-specific IgG antibodies and analyze the impact of health status and vaccination timing on immune persistence, thereby providing data support for public health policies.

 

 

Research Methods and Core Experiments

The authors employed a cross-sectional study design, enrolling 156 adolescents aged 13–15 with documented records of two MMR vaccine doses. Serum IgG antibody levels against measles virus, mumps virus, rubella virus, and varicella-zoster virus were quantitatively detected using commercial ELISA kits. The study strictly established analytical cutoff values, treating equivocal results as negative in the primary analysis and as positive in sensitivity analysis to assess the robustness of the detection method. Additionally, linear regression was used to analyze the associations between age, time since vaccination, and pediatric health status classification with antibody concentrations.

Key Conclusions and Perspectives

• Seropositivity rates varied significantly among infections: Rubella was the highest (81.4%), while measles was the lowest (41.0%), indicating a severe gap in measles antibody protection levels among the fully vaccinated population.
• Measles antibody geometric mean concentration (GMC) was the lowest, and detection results were highly dependent on the cutoff values of the assay kits, suggesting that ELISA methods may underestimate the true seroprevalence.
• The seropositivity rate for mumps antibodies was only 53.2%, with no significant trend of antibody decline observed with increasing age or time, possibly reflecting that antibody levels have reached a plateau or are limited by the sensitivity of the detection method.
• The seropositivity rate for varicella antibodies was 57.7%. Despite originating from natural infection, some individuals had antibody levels below the diagnostic threshold, suggesting potential individual variations in the mechanisms maintaining immune memory after natural infection.
• The study found no significant impact of pediatric health status (healthy group, functional abnormality group, chronic disease remission group) on antibody concentrations, indicating that baseline health status is not a major factor contributing to immunity gaps.

Research Significance and Prospects

These findings have important implications for vaccine efficacy evaluation and clinical monitoring. First, they emphasize that relying solely on ELISA detection of IgG antibodies may not accurately reflect the true immune protection status; future studies should combine neutralization assays or cellular immunity tests for validation. Second, the low seropositivity rates for measles and mumps suggest a need to focus on enhancing long-term immunogenicity in drug development or vaccine improvement, and to consider introducing booster doses at specific age groups. Finally, this study provides real-world data for disease modeling, aiding in more precise prediction of outbreak risks and optimization of immunization programs.

 

 

Conclusion

Through a rigorous serological survey, this study reveals significant immunity gaps against measles and mumps in adolescents despite an apparently robust vaccination system. This finding not only challenges the traditional notion that two doses of the MMR vaccine provide lifelong protection but also highlights the urgency of re-evaluating serological protection thresholds. Translating from laboratory to clinical application, the study underscores the limitations of single antibody testing and calls for the inclusion of more comprehensive immune assessment indicators, such as cellular immune responses and antibody affinity analysis, in future disease surveillance systems. This plays a foundational role in building a more robust herd immunity barrier to prevent the resurgence of vaccine-preventable diseases and provides critical evidence for public health departments to formulate scientific booster immunization strategies.

 

Mikhail P Kostinov, Ivan S Samolygo, Aristitsa M Kostinova, Anton S Antishin, and Svetlana I Erdes. Seroprevalence of IgG Antibodies to Measles, Mumps, Rubella and Varicella in Adolescents with Documented Two-Dose MMR Vaccination: Cross-Sectional Study. Antibodies.